Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

DIREVO Biotech AG

Request full access

Customized solutions for various industries

Cologne, GermanyFounded 2000Energy

About DIREVO Biotech AG

In 2000, a new company, DIREVO Biotech AG, was spun out of the renowned Max Planck Institute in Germany to commercialize the groundbreaking research of its co-founder, Nobel Laureate Manfred Eigen. The company was built on a powerful concept called directed evolution. Its core business was a high-throughput technology platform designed to rapidly discover and optimize proteins and enzymes for both the pharmaceutical and industrial sectors. The playbook was clear: create a factory for better bio-molecules. DIREVO's platform could engineer superior therapeutic proteins for drug development or create more efficient enzymes for industrial processes, partnering with giants like Danisco. This strategy attracted significant investment and positioned the company as a leader in the specialized field of protein engineering. The pivotal moment arrived in September 2008. Bayer HealthCare announced it would acquire DIREVO Biotech in an all-cash deal valued at €210 million. Bayer sought to integrate DIREVO's powerful biopharmaceutical discovery engine to bolster its own pipeline of biological drugs. In a concurrent and strategic move, DIREVO's industrial biotechnology unit was spun off into a separate entity, DIREVO Industrial Biotechnology GmbH, backed by the original investors to continue its work outside of pharma. This allowed the core pharmaceutical technology to be absorbed by a major player while letting the industrial side of the business continue on its own trajectory.

Source: Dealroom company data

DIREVO Biotech AG in the Cologne ecosystem

Live from Dealroom

The DIREVO Biotech AG office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • Techno Venture Management
  • Mulligan BioCapital
  • Sanders Morris Harris
  • Danish Venture Capital and Private Equity Association

Series B and later4 investors entered at this stage

  • NRW.BANK
  • Danisco A/S
  • TVM Capital Life Science
  • Signet Healthcare Partners
Team profiled 8 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇩🇪 Germany100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about DIREVO Biotech AG on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See DIREVO Biotech AG on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.